

(19) World Intellectual Property
Organization
International Bureau



28 FEB 2005



(43) International Publication Date
11 March 2004 (11.03.2004)


PCT

(10) International Publication Number
WO 2004/021008 A2

- (51) International Patent Classification⁷: **G01N 33/574**
- (21) International Application Number:
PCT/CA2003/001310
- (22) International Filing Date: 28 August 2003 (28.08.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/407,333 28 August 2002 (28.08.2002) US
- (71) Applicants (for all designated States except US): **MOUNT SINAI HOSPITAL [CA/CA]**; 600 University Avenue, Toronto, Ontario M5G 1X5 (CA). **YOUSEF, George [EG/CA]**; 300 Prince Phillip Drive, St. John's, Newfoundland & Labrador A1B 3V6 (CA).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **DIAMANDIS, Eleftherios, P. [CA/CA]**; 44 Gerrard Street West, Suite 1504, Toronto, Ontario M5G 2K2 (CA).
- (74) Agent: **KURDYDYK, Linda**; McCarthy Tetrault, Suite 4700, P.O.Box 48, 66 Wellington Street West, Toronto Dominion Bank Tower, Toronto, Ontario M5K 1E6 (CA).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: METHODS FOR DETECTING BREAST AND OVARIAN CANCER



(57) **Abstract:** Kallikrein 5 constitutes a novel biomarker for diagnosis, treatment and monitoring of breast and ovarian cancer. A method is provided for diagnosing and monitoring breast or ovarian cancer or a predisposition to breast or ovarian cancer, in a subject comprising detecting kallikrein 5 in a sample from the subject. Imaging methods, screening methods for test agents for inhibiting breast or ovarian cancer, and therapeutic applications based on kallikrein 5 are also described.